SEC Company Response from AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946) (AXIM) — Jun 21, 2021
AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946)
Date: June 21, 2021 · CIK: 0001514946 · Accession: 0001078782-21-000578
AI Filing Summary & Sentiment
File numbers found in text: 333-256162
Letter
Sec Correspondence
AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E. Suite 114
San Diego, CA 92121
June 21, 2021
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities & Exchange Commission (the “Commission”)
100 F Street, N.E.
Washington, D.C. 20549
Attention:
David Gessert
Re:
AXIM Biotechnologies, Inc.
Registration Statement on Form S-1/A
Filed June 9, 2021
File No. 333-256162
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, AXIM Biotechnologies, Inc. (the “Company”) hereby requests that the effective date for the above-referenced Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-256162) be accelerated so that it will be declared effective at 5:00 PM Eastern Standard Time on June 22, 2021, or as soon thereafter as is practicable.
The undersigned, on behalf of the Company, acknowledges the following:
·should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
·the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
·the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States
Sincerely,
AXIM BIOTECHNOLOGIES, INC.
Show Raw Text
CORRESP 1 filename1.htm Sec Correspondence AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 June 21, 2021 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission (the “Commission”) 100 F Street, N.E. Washington, D.C. 20549 Attention: David Gessert Re: AXIM Biotechnologies, Inc. Registration Statement on Form S-1/A Filed June 9, 2021 File No. 333-256162 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, AXIM Biotechnologies, Inc. (the “Company”) hereby requests that the effective date for the above-referenced Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-256162) be accelerated so that it will be declared effective at 5:00 PM Eastern Standard Time on June 22, 2021, or as soon thereafter as is practicable. The undersigned, on behalf of the Company, acknowledges the following: ·should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; ·the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and ·the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States Sincerely, AXIM BIOTECHNOLOGIES, INC. /s/ John W. Huemoeller II John W. Huemoeller II President